IDNA vs. SBIO
IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) and SBIO (ALPS Medical Breakthroughs ETF) are both Health & Biotech Equities funds - IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index while SBIO tracks the S-Network Medical Breakthroughs Index. Both are passively managed. Over the past 5 years, IDNA returned -8.26%/yr vs 2.56%/yr for SBIO. Their correlation of 0.85 suggests significant overlap in exposure. IDNA charges 0.47%/yr vs 0.50%/yr for SBIO.
Performance
IDNA vs. SBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IDNA achieves a 9.51% return, which is significantly higher than SBIO's -1.78% return.
IDNA
- 1D
- -2.18%
- 1M
- -2.18%
- YTD
- 9.51%
- 6M
- 10.53%
- 1Y
- 41.74%
- 3Y*
- 6.48%
- 5Y*
- -8.26%
- 10Y*
- —
SBIO
- 1D
- -4.73%
- 1M
- -6.02%
- YTD
- -1.78%
- 6M
- 5.47%
- 1Y
- 67.29%
- 3Y*
- 17.25%
- 5Y*
- 2.56%
- 10Y*
- 7.86%
IDNA vs. SBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 9.51% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
SBIO ALPS Medical Breakthroughs ETF | -1.78% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 25.73% |
Correlation
The correlation between IDNA and SBIO is 0.83, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.83 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.84 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.85 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.85 |
The correlation between IDNA and SBIO has been stable across timeframes, ranging from 0.83 to 0.85 - a consistent structural relationship.
IDNA vs. SBIO - Sectors Allocation Comparison
Sectors
IDNA
SBIO
Healthcare
Industrials
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IDNA
SBIO
Industrials
IDNA
SBIO
-
Basic Materials
IDNA
-
SBIO
-
Communication Services
IDNA
-
SBIO
-
Consumer Cyclical
IDNA
-
SBIO
-
Consumer Defensive
IDNA
-
SBIO
-
Energy
IDNA
-
SBIO
-
Financial Services
IDNA
-
SBIO
Real Estate
IDNA
-
SBIO
-
Technology
IDNA
-
SBIO
-
Utilities
IDNA
-
SBIO
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IDNA vs. SBIO — Risk / Return Rank
IDNA
SBIO
IDNA vs. SBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | SBIO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.71 | 2.30 | -0.59 |
Sortino ratioReturn per unit of downside risk | 2.48 | 3.17 | -0.69 |
Omega ratioGain probability vs. loss probability | 1.28 | 1.37 | -0.09 |
Calmar ratioReturn relative to maximum drawdown | 4.09 | 5.74 | -1.65 |
Martin ratioReturn relative to average drawdown | 11.79 | 17.50 | -5.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IDNA | SBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.71 | 2.30 | -0.59 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.29 | 0.08 | -0.37 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.24 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.21 | -0.11 |
Drawdowns
IDNA vs. SBIO - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than SBIO's maximum drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for IDNA and SBIO.
Loading charts...
Drawdown Indicators
| IDNA | SBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -63.06% | -5.20% |
Max Drawdown (1Y)Largest decline over 1 year | -10.66% | -12.66% | +2.00% |
Max Drawdown (3Y)Largest decline over 3 years | -29.73% | -42.44% | +12.71% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | -53.10% | -15.16% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.06% | — |
Current DrawdownCurrent decline from peak | -46.01% | -17.95% | -28.06% |
Average DrawdownAverage peak-to-trough decline | -36.24% | -28.45% | -7.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.70% | 4.15% | -0.45% |
Volatility
IDNA vs. SBIO - Volatility Comparison
The current volatility for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) is 7.24%, while ALPS Medical Breakthroughs ETF (SBIO) has a volatility of 9.94%. This indicates that IDNA experiences smaller price fluctuations and is considered to be less risky than SBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IDNA | SBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.24% | 9.94% | -2.70% |
Volatility (6M)Calculated over the trailing 6-month period | 18.21% | 22.86% | -4.65% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.51% | 29.55% | -5.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.42% | 33.55% | -5.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.53% | 33.18% | -3.65% |
IDNA vs. SBIO - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than SBIO's 0.50% expense ratio.
Dividends
IDNA vs. SBIO - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.08%, while SBIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.08% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
Frequently Asked Questions
IDNA and SBIO have a correlation of 0.83, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SBIO has higher volatility (9.94%) compared to IDNA (7.24%). In terms of maximum drawdown, IDNA dropped -68.26% vs SBIO's -63.06%.
On 5-year performance, SBIO leads with 2.56% vs -8.26% for IDNA. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 7.24%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, SBIO has performed better with a 2.56% return vs -8.26%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IDNA is cheaper with a 0.47% expense ratio, compared with 0.50% for SBIO.
IDNA has the higher dividend yield at 1.08%, compared with 0.00% for SBIO.
IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while SBIO tracks S-Network Medical Breakthroughs Index. They also come from different issuers: iShares and SS&C. Their fees differ too: 0.47% for IDNA and 0.50% for SBIO.
SBIO currently has the higher Sharpe Ratio (2.30 vs 1.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IDNA and SBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer